about
Rational design of an organometallic glutathione transferase inhibitorc-Jun N-terminal kinase activation by nitrobenzoxadiazoles leads to late-stage autophagy inhibitionAllergic contact dermatitis: novel mechanisms and therapeutic perspectives.The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasisA new nitrobenzoxadiazole-based GSTP1-1 inhibitor with a previously unheard of mechanism of action and high stability.TNFR-Associated Factor-2 (TRAF2): Not Only a Trimer.A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.Synthesis and structure--activity relationship of new cytotoxic agents targeting human glutathione-S-transferases.Nitrobenzoxadiazole-based GSTP1-1 inhibitors containing the full peptidyl moiety of (pseudo)glutathione.Monomer-dimer equilibrium in glutathione transferases: a critical re-examination.New insight into the interaction of TRAF2 C-terminal domain with lipid raft microdomains.Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs.The fragile X mental retardation protein regulates tumor invasiveness-related pathways in melanoma cells.Studies of Glutathione Transferase P1-1 Bound to a Platinum(IV)-Based Anticancer Compound Reveal the Molecular Basis of Its ActivationA new target for gold(I) compounds: Glutathione-S-transferase inhibition by auranofinEffective squaric acid dibutylester immunotherapy is associated with a reduction of skin infiltrating T-helper (Th)1 and Th17 cells in alopecia areata patientsCopper homeostasis as target of both consolidated and innovative strategies of anti-tumor therapySynthesis and characterisation of a new benzamide-containing nitrobenzoxadiazole as a GSTP1-1 inhibitor endowed with high stability to metabolic hydrolysisA structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1
P50
Q27655297-E5030904-895B-48AC-9AE1-B69D2159D62DQ36549591-39BAEC63-FFCA-4A1D-B015-5AAD29205B97Q37734525-4E74EC90-67B7-46D9-A007-EA592C484E43Q38720370-FB6CBFC3-C1DE-46ED-B4AE-85FC31501AEFQ38720837-985BE150-72D7-4F32-B82F-7207FF4D5959Q38833886-A78D0FFB-EA30-4579-B996-D07ECDCAAF46Q38896939-0E2C153C-F64C-472A-8FAC-6D2A58F0B228Q38933414-C9E1529E-49DB-4C3C-99CA-CE2E7B9E13C2Q40584612-F3400A0F-9C91-4C23-9376-73174BA31DCAQ43268662-66919F75-3F3B-4377-9F35-269F9964E9B1Q46708157-51F1B9C8-4BAB-4317-8395-F818A707402BQ46964649-343FF7EA-9538-4F00-9034-0685C5C50BA3Q47396492-826FE5E6-17FD-4E29-A081-12A7D8ED3623Q57838180-9ED2C2E0-79F3-4E0D-A9F4-4D105835588EQ60212469-9D189157-21B7-4C79-B800-EA661C3203EFQ86246178-9E45B842-5C56-4AF8-B5BD-56EE76FC459BQ92181329-54F82846-7722-4FD2-BF72-94AA5C7A15A1Q92555460-05358D2F-69DA-4266-9018-B07B83728AD6Q92916618-063BAA58-7356-456E-B49E-BD6C541CDB87
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Anastasia De Luca
@ast
Anastasia De Luca
@en
Anastasia De Luca
@es
Anastasia De Luca
@nl
type
label
Anastasia De Luca
@ast
Anastasia De Luca
@en
Anastasia De Luca
@es
Anastasia De Luca
@nl
prefLabel
Anastasia De Luca
@ast
Anastasia De Luca
@en
Anastasia De Luca
@es
Anastasia De Luca
@nl
P108
P106
P1153
55253185700
P31
P496
0000-0002-6532-989X